HPS Pharmacies wishes to advise that Boehringer Ingelheim is discontinuing all strengths of Twynsta® (telmisartan + amlodipine) and Pritor/Amlodipine (telmisartan + amlodipine) tablets.
All strengths of these products are set to be discontinued on 31 December 2025. Supplies are expected to be exhausted by 1 February 2026.
These products are indicated for the treatment of hypertension. Their discontinuation is related to a reduction in demand. There are no safety or quality concerns associated with these products.
There is currently no identical combination products marketed in Australia. However, telmisartan and amlodipine are available separately in multiple brands.
Retain this notice in a prominent position, including in other related business units for at least one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Boehringer Ingelheim on (02) 8875 8800 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates